Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that its previously announced tender offer (the “Offer”) to acquire... Read more.
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
Approval by European Commission would expand Reblozyl’s indication to include first-line treatment of anemia in adults with MDS in Europe In the pivotal Phase... Read more.
UnitedHealth Group Board Authorizes Payment of Quarterly Dividend
–(BUSINESS WIRE)–The UnitedHealth Group (NYSE: UNH) board of directors has authorized payment of a cash dividend of $1.88 per share, to be paid on March... Read more.
UnitedHealth Group Board Authorizes Payment of Quarterly Dividend
–(BUSINESS WIRE)–The UnitedHealth Group (NYSE: UNH) board of directors has authorized payment of a cash dividend of $1.88 per share, to be paid on March... Read more.
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress
Results of the two-year LIBERTY studies demonstrate that CT-P13 SC provides long-term clinical benefits and safety, with the convenience of subcutaneous (SC) administration,... Read more.
Docebo Reports Fourth Quarter and Fiscal Year 2023 Results
TORONTO–(BUSINESS WIRE)–Docebo Inc. (NASDAQ: DCBO; TSX:DCBO) (“Docebo” or the “Company”), a leading learning platform provider with a foundation... Read more.
CenterOak Partners Announces Sale of SurfacePrep
DALLAS–(BUSINESS WIRE)–CenterOak Partners LLC (“CenterOak”), a Dallas-based private equity firm, today announced the sale of SurfacePrep (the “Company”),... Read more.
itel Grand 2024 Brand Launch, the Industry’s Biggest Event at the Egyptian Pyramids
CAIRO–(BUSINESS WIRE)–#5G–itel, the global leading smart life brand committed to providing affordable and good quality consumer electronic products,... Read more.
Global Blue Delivers a Strong Q3 FY23/24 Financial Performance, With Continued Double-digit Growth, Healthy Profitability, and Active de-Leveraging
Strong YoY growth in Adjusted EBITDA of 65.2% to €39.8m in Q3 FY23/24 and 102.3% to €114.7m in 9M FY23/24, with 9M Adjusted EBITDA margin of 36.2% Continued... Read more.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
Opinion granted based on positive overall survival and event-free survival results from the Phase 3 KEYNOTE-671 trial First opinion to be granted for an anti-PD-1/L1... Read more.